NASDAQ:PTLA Portola Pharmaceuticals (PTLA) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free PTLA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$18.03▼$18.0350-Day Range$18.03▼$18.0352-Week Range$5.31▼$31.73VolumeN/AAverage Volume3.17 million shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Portola Pharmaceuticals alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Portola Pharmaceuticals Stock (NASDAQ:PTLA)Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.Read More Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). PTLA Stock News HeadlinesApril 15, 2023 | usnews.comPortola MiddleMarch 25, 2023 | sfgate.comFault lines in Portola ValleyApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.March 23, 2023 | usnews.comPortola-Butler Continuation High SchoolFebruary 18, 2023 | yahoo.comPortola, United States - Weather Forecasts | Maps | News - Yahoo WeatherDecember 31, 2022 | forbes.comEagle PharmaceuticalsNovember 21, 2022 | markets.businessinsider.comBerman Tabacco Announces Class Action Settlement In Securities Litigation Involving Purchasers of Portola Pharmaceuticals, Inc. Common StockOctober 7, 2022 | investing.comPTLA_old Historical DataApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.September 29, 2022 | seekingalpha.comKPRX Kiora Pharmaceuticals, Inc.See More Headlines Receive PTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Portola Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PTLA CUSIPN/A CIK1269021 Webwww.portola.com Phone650-246-7000FaxN/AEmployees324Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-290,660,000.00 Net Margins-232.73% Pretax MarginN/A Return on Equity-267.86% Return on Assets-54.66% Debt Debt-to-Equity Ratio4.77 Current Ratio4.87 Quick Ratio4.82 Sales & Book Value Annual Sales$116.64 million Price / Sales12.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book10.80Miscellaneous Outstanding Shares78,484,000Free FloatN/AMarket Cap$1.42 billion OptionableOptionable Beta2.32 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMs. Mardi C. Dier (Age 55)Exec. VP, Chief Bus. Officer & CFO Dr. John T. Curnutte (Age 67)Exec. VP and Head of R&D Mr. J. Scott Garland M.B.A. (Age 50)MBA, Pres & CEO Cara MillerVP of Investor Relations and Corp. CommunicationsMr. John B. Moriarty Jr. (Age 51)Exec. VP, Gen. Counsel & Sec. Key CompetitorsArcus BiosciencesNYSE:RCUSKura OncologyNASDAQ:KURAANI PharmaceuticalsNASDAQ:ANIPMorphicNASDAQ:MORFAkero TherapeuticsNASDAQ:AKROView All Competitors PTLA Stock Analysis - Frequently Asked Questions How were Portola Pharmaceuticals' earnings last quarter? Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.14. The biopharmaceutical company had revenue of $26.40 million for the quarter, compared to the consensus estimate of $33.88 million. Portola Pharmaceuticals had a negative net margin of 232.73% and a negative trailing twelve-month return on equity of 267.86%. Portola Pharmaceuticals's revenue for the quarter was up 18.9% compared to the same quarter last year. During the same quarter last year, the company posted ($1.02) earnings per share. What other stocks do shareholders of Portola Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Amarin (AMRN), Exelixis (EXEL), NVIDIA (NVDA), Geron (GERN), ACADIA Pharmaceuticals (ACAD) and Aileron Therapeutics (ALRN). This page (NASDAQ:PTLA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portola Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
